Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
With
Josep Carreras Leukaemia Research Institute
Instituto de Salud Carlos III
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Classic Hodgkin lymphoma:
* Relapsed patients after autologous hematopoietic stem cell transplantation who have already received Brentuximab-Vedotin and anti-PDL1 antibodies, OR
* Primarily refractory patients who do not reach CR after rescue, including Brentuximab-Vedotin and anti-PDL1 antibodies.
Anaplastic large T-cell lymphoma (ALK+/ALK-) and peripheral T-cell lymphoma (NOS/Angioimmunoblastic):
* \>90% of tumor cells expressing CD30 determined by immunohistochemistry, AND
* Relapsed patients after autologous hematopoietic stem cell transplantation, OR
* Primarily refractory patients (after first line, including anthracycline) who do not achieve CR after rescue.
* All patients must sign an informed consent before starting any procedure.
* All patients must have measurable disease (detected by PET-CT) at the time of inclusion.
* Performance status: ECOG 0-1
* FEV1\> 39%; DLCO and FVC\> 39% of NV.
* No significant ventricular dysfunction: EF \>45%.
* Total bilirubin and transaminases \<3 times the maximum normal value, unless attributable to lymphoma.
* Creatinine \<2 times the normal maximum value and clearance\> 40 mL/min.
